Faster detection of asymptomatic COVID-19 cases among care home staff in England through the combination of SARS-CoV-2 testing technologies.

Faster detection of asymptomatic COVID-19 cases among care home staff in England through the combination of SARS-CoV-2 testing technologies.

Publication date: Mar 29, 2024

To detect SARS-CoV-2 amongst asymptomatic care home staff in England, a dual-technology weekly testing regime was introduced on 23 December 2020. A lateral flow device (LFD) and quantitative reverse transcription polymerase chain reaction (qRT-PCR) test were taken on the same day (day 0) and a midweek LFD test was taken three to four days later. We evaluated the effectiveness of using dual-technology to detect SARS-CoV-2 between December 2020 to April 2021. Viral concentrations derived from qRT-PCR were used to determine the probable stage of infection and likely level of infectiousness. Day 0 PCR detected 1,493 cases of COVID-19, of which 53% were in the early stages of infection with little to no risk of transmission. Day 0 LFD detected 83% of cases that were highly likely to be infectious. On average, LFD results were received 46. 3 h earlier than PCR, enabling removal of likely infectious staff from the workplace quicker than by weekly PCR alone. Demonstrating the rapidity of LFDs to detect highly infectious cases could be combined with the ability of PCR to detect cases in the very early stages of infection. In practice, asymptomatic care home staff were removed from the workplace earlier, breaking potential chains of transmission.

Open Access PDF

Concepts Keywords
Asymptomatic Asymptomatic
England Care
Pcr Covid
Viral Day
Weekly Detect
Dual
England
Home
Infection
Infectious
Lfd
Pcr
Sars
Staff
Testing

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Etoperidone
disease VO device
disease VO effectiveness
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH Rida
drug DRUGBANK N-acetylsulfanilyl chloride
disease MESH Emergencies
drug DRUGBANK Isoxaflutole
disease IDO contact tracing
disease VO dead
disease IDO symptom
disease VO protocol
drug DRUGBANK Trestolone
disease VO time
disease VO nose
drug DRUGBANK Methionine
disease MESH severe acute respiratory syndrome
disease VO efficiency
drug DRUGBANK Gold
drug DRUGBANK L-Phenylalanine
disease MESH viral shedding
disease VO monthly
disease VO population
disease VO effective
drug DRUGBANK Indoleacetic acid
disease IDO assay
disease VO report
disease IDO infectivity
disease IDO host
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)